Table 1.
Baseline characteristics. Values are numbers (percentages) unless stated otherwise
| Characteristics | Primary study population (n=23 308) | P2Y12 inhibitor (n=11 634) | Aspirin + P2Y12 inhibitor (n=11 674) | Difference (95% CI) | P value |
|---|---|---|---|---|---|
| Study ID: | |||||
| DACAB | 334 (1.4) | 166 (1.4) | 168 (1.4) | 0.0% (–0.3% to 0.3%) | 0.95 |
| GLASSY | 7509 (32.2) | 3753 (32.3) | 3756 (32.2) | 0.1% (–1.1% to 1.3%) | 0.90 |
| SMART-CHOICE | 2926 (12.6) | 1455 (12.5) | 1471 (12.6) | –0.1% (–0.9% to 0.8%) | 0.84 |
| STOPDAPT-2 | 3003 (12.9) | 1496 (12.9) | 1507 (12.9) | –0.1% (–0.9% to 0.8%) | 0.92 |
| TICO | 3004 (12.9) | 1499 (12.9) | 1505 (12.9) | –0.0% (–0.9% to 0.9%) | >0.99 |
| TWILIGHT | 6532 (28.0) | 3265 (28.1) | 3267 (28.0) | 0.1% (–1.1% to 1.2%) | 0.89 |
| Mean (SD) age, years | 64.8 (10.6) (n=23 308) | 64.8 (10.6) (n=11 634) | 64.9 (10.6) (n=11 674) | –0.1 (–0.3 to 0.2) | 0.58 |
| Age ≥65 years | 12 194 (52.3) | 6094 (52.4) | 6100 (52.3) | 0.1% (–1.2% to 1.4%) | 0.85 |
| Female sex | 5423 (23.3) | 2717 (23.4) | 2706 (23.2) | 0.2% (–0.9% to 1.3%) | 0.75 |
| Mean (SD) height, m | 1.7 (0.1) (n=22 951) | 1.7 (0.1) (n=11 455) | 1.7 (0.1) (n=11 496) | 0.0 (–0.0 to 0.0) | 0.32 |
| Mean (SD) weight, kg | 76.6 (17.3) (n=22 958) | 76.7 (17.3) (n=11 461) | 76.5 (17.2) (n=11 497) | 0.2 (–0.3 to 0.6) | 0.42 |
| Mean (SD) body mass index | 26.9 (4.8) (n=22 948) | 26.9 (4.8) (n=11 455) | 26.9 (4.8) (n=11 493) | 0.0 (–0.1 to 0.1) | 0.79 |
| Geographical region: | 0.99 | ||||
| Asia | 10 318 (44.3) | 5146 (44.2) | 5172 (44.3) | –0.1% (–1.3% to 1.2%) | 0.91 |
| North America | 2972 (12.8) | 1484 (12.8) | 1488 (12.7) | 0.0% (–0.8% to 0.9%) | 0.98 |
| Western Europe | 7848 (33.7) | 3917 (33.7) | 3931 (33.7) | –0.0% (–1.2% to 1.2%) | >0.99 |
| Eastern Europe | 2170 (9.3) | 1087 (9.3) | 1083 (9.3) | 0.1% (–0.7% to 0.8%) | 0.87 |
| Diabetes mellitus | 7419/23 304 (31.8) | 3744/11 630 (32.2) | 3675/11 674 (31.5) | 0.7% (–0.5% to 1.9%) | 0.24 |
| Insulin treated diabetes | 1543/21 104 (7.3) | 746/10 547 (7.1) | 797/10 557 (7.5) | –0.5% (–1.2% to 0.2%) | 0.18 |
| Current cigarette smoker | 6271/23 299 (26.9) | 3134/11 630 (26.9) | 3137/11 669 (26.9) | 0.1% (–1.1% to 1.2%) | 0.91 |
| Hypercholesterolaemia | 14 695/23 030 (63.8) | 7298/11 494 (63.5) | 7397/11 536 (64.1) | –0.6% (–1.9% to 0.6%) | 0.32 |
| Hypertension | 16 005/23 286 (68.7) | 7985/11 624 (68.7) | 8020/11 662 (68.8) | –0.1% (–1.3% to 1.1%) | 0.90 |
| Liver disease | 33/20 048 (0.2) | 21/10 013 (0.2) | 12/10 035 (0.1) | 0.1% (–0.0% to 0.2%) | 0.11 |
| Peripheral artery disease | 1323/20 267 (6.5) | 633/10 114 (6.3) | 690/10 153 (6.8) | –0.5% (–1.2% to 0.1%) | 0.12 |
| Previous myocardial infarction | 4438/23 297 (19.0) | 221/11 626 (19.1) | 2217/11 671 (19.0) | 0.1% (–0.9% to 1.1%) | 0.83 |
| Previous PCI | 6959/22 966 (30.3) | 3440/11 464 (30.0) | 3519/11 502 (30.6) | –0.6% (–1.8% to 0.6%) | 0.33 |
| Previous CABG | 1250/23 300 (5.4) | 606/11 629 (5.2) | 644/11 671 (5.5) | –0.3% (–0.9% to 0.3%) | 0.29 |
| Previous stroke | 733/23 298 (3.1) | 343/11 626 (3.0) | 390/11 672 (3.3) | –0.4% (–0.8% to 0.1%) | 0.09 |
| Previous bleeding | 265/23 291 (1.1) | 132/11 623 (1.1) | 133/11 668 (1.1) | 0.0% (–0.3% to 0.3%) | 0.97 |
| History of chronic kidney disease | 3823/23 031 (16.6) | 1892/11 491 (16.5) | 1931/11 540 (16.7) | –0.3% (–1.2% to 0.7%) | 0.58 |
| Chronic lung disease | 826/17 238 (4.8) | 403/8609 (4.7) | 423/8629 (4.9) | –0.2% (–0.9% to 0.4%) | 0.49 |
| Clinical presentation: | (n=23 305) | (n=11 633) | (n=11 672) | 0.53 | |
| Chronic coronary syndrome | 9339 (40.1) | 4685 (40.3) | 4654 (39.9) | 0.4% (–0.9% to 1.7%) | 0.53 |
| Acute coronary syndrome | 13 966 (59.9) | 6948 (59.7) | 7018 (60.1) | –0.4% (–1.7% to 0.9%) | 0.53 |
| Unstable angina | 5579 (39.9) | 2752 (39.6) | 2827 (40.3) | –0.7% (–2.3% to 1.0%) | 0.41 |
| Non-STEMI | 5122 (36.7) | 2543 (36.6) | 2579 (36.7) | –0.1% (–1.7% to 1.5%) | 0.86 |
| STEMI | 3265 (23.4) | 1653 (23.8) | 1612 (23.0) | 0.8% (–0.6% to 2.2%) | 0.25 |
| Aspirin on admission | 13 182/20 301 (64.9) | 6581/10 137 (64.9) | 6601/10 164 (64.9) | 0.0% (–1.3% to 1.3%) | 0.97 |
| Mean (SD) PRECISE-DAPT score* | 16.5 (9.5) (n=22 017) | 16.5 (9.5) (n=10 971) | 16.6 (9.6) (n=11 046) | –0.1 (–0.3 to 0.2) | 0.56 |
| PRECISE-DAPT score ≥25 | 3730/22 017 (16.9) | 1850/10 971 (16.9) | 1880/11 046 (17.0) | –0.2% (–1.1% to 0.8%) | 0.76 |
| Median (IQR) creatinine clearance (MDRD), mL/min | 84.4 (70.0-100.0) (n=22 961) | 84.7 (70.1-100.2) (n=11 455) | 84.2 (69.7-99.8) (n=11 506) | 0.2 (–2.2 to 2.6) | 0.19 |
| Mean (SD) haemoglobin, g/dL | 14.0 (1.9) (n=22 638) | 14.0 (1.7) (n=11 294) | 14.0 (2.1) (n=11 344) | –0.0 (–0.1 to 0.0) | 0.75 |
| Mean (SD) LVEF, % | 56.4 (11.1) (n=13 742) | 56.3 (11.0) (n=6851) | 56.4 (11.2) (n=6891) | –0.1 (–0.5 to 0.3) | 0.64 |
ACS=acute coronary syndrome; CABG=coronary artery bypass grafting; CCS=chronic coronary syndrome; LVEF=left ventricular ejection fraction; MDRD=Modification of Diet in Renal Disease; PCI=percutaneous coronary intervention; STEMI=ST-segment elevation myocardial infarction.
*
Includes five items: age, creatinine clearance, white blood cell count, haemoglobin, and history of bleeding.